Series A · Healthtech · Stockholm, Sweden · Founded 2014 · 11–50 employees
Sigrid Therapeutics develops SiPore, a patented bioengineered silica technology that prevents and treats metabolic diseases like prediabetes, diabetes, and obesity through non-pharmaceutical means. Their flagship product SiPore21 works by mechanically trapping digestive enzymes in the gut to slow carbohydrate and fat breakdown, reducing blood sugar spikes and supporting weight loss. The company has completed four clinical trials including the large SHINE trial across 27 European clinics, with regulatory approval expected in Q2 2025 (US) and Q2 2026 (EU). Founded in 2014, they've raised approximately $17.5M and received recognition as a Fierce 15 leading medtech company.
No open roles listed right now.